JPWO2020097265A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020097265A5 JPWO2020097265A5 JP2021524225A JP2021524225A JPWO2020097265A5 JP WO2020097265 A5 JPWO2020097265 A5 JP WO2020097265A5 JP 2021524225 A JP2021524225 A JP 2021524225A JP 2021524225 A JP2021524225 A JP 2021524225A JP WO2020097265 A5 JPWO2020097265 A5 JP WO2020097265A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- compound
- optionally substituted
- item
- membered heterocycle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 271
- 125000000623 heterocyclic group Chemical group 0.000 claims description 216
- 150000003839 salts Chemical class 0.000 claims description 199
- 150000001875 compounds Chemical class 0.000 claims description 187
- 229910052736 halogen Inorganic materials 0.000 claims description 165
- 150000002367 halogens Chemical class 0.000 claims description 164
- 125000001424 substituent group Chemical group 0.000 claims description 134
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 82
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 46
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 42
- 229910052799 carbon Inorganic materials 0.000 claims description 40
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 37
- 125000003118 aryl group Chemical group 0.000 claims description 33
- 125000001188 haloalkyl group Chemical group 0.000 claims description 33
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 125000005842 heteroatom Chemical group 0.000 claims description 19
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 16
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 16
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 13
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 12
- 125000006583 (C1-C3) haloalkyl group Chemical group 0.000 claims description 11
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 10
- 125000001072 heteroaryl group Chemical group 0.000 claims description 10
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 10
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 6
- 230000002232 neuromuscular Effects 0.000 claims description 6
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 5
- 125000002950 monocyclic group Chemical group 0.000 claims description 5
- 206010061533 Myotonia Diseases 0.000 claims description 4
- 125000000304 alkynyl group Chemical group 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 3
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims description 2
- 201000009110 Oculopharyngeal muscular dystrophy Diseases 0.000 claims description 2
- 125000002393 azetidinyl group Chemical group 0.000 claims description 2
- 230000001815 facial effect Effects 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000000943 scapulohumeral muscular dystrophy Diseases 0.000 claims description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 8
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims 1
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 claims 1
- 208000007101 Muscle Cramp Diseases 0.000 claims 1
- 208000005392 Spasm Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 27
- 125000006193 alkinyl group Chemical group 0.000 description 20
- 150000002431 hydrogen Chemical class 0.000 description 13
- 125000005843 halogen group Chemical group 0.000 description 9
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 125000004429 atom Chemical group 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 description 4
- 208000008238 Muscle Spasticity Diseases 0.000 description 3
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 3
- 238000001415 gene therapy Methods 0.000 description 3
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 description 2
- 208000016285 Movement disease Diseases 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000004118 muscle contraction Effects 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 208000022306 Cerebral injury Diseases 0.000 description 1
- 108010069091 Dystrophin Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 208000019430 Motor disease Diseases 0.000 description 1
- 208000029549 Muscle injury Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 201000011252 Phenylketonuria Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 206010008129 cerebral palsy Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 229960001145 deflazacort Drugs 0.000 description 1
- FBHSPRKOSMHSIF-GRMWVWQJSA-N deflazacort Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)=N[C@@]3(C(=O)COC(=O)C)[C@@]1(C)C[C@@H]2O FBHSPRKOSMHSIF-GRMWVWQJSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000001016 myotrophic effect Effects 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022174578A JP7357135B2 (ja) | 2018-11-06 | 2022-10-31 | ピリダジノン化合物およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862756539P | 2018-11-06 | 2018-11-06 | |
| US62/756,539 | 2018-11-06 | ||
| PCT/US2019/060155 WO2020097265A1 (en) | 2018-11-06 | 2019-11-06 | Pyridazinone compounds and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022174578A Division JP7357135B2 (ja) | 2018-11-06 | 2022-10-31 | ピリダジノン化合物およびその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022506685A JP2022506685A (ja) | 2022-01-17 |
| JP2022506685A5 JP2022506685A5 (https=) | 2022-05-17 |
| JPWO2020097265A5 true JPWO2020097265A5 (https=) | 2022-05-17 |
| JP7170133B2 JP7170133B2 (ja) | 2022-11-11 |
Family
ID=69160035
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021524225A Active JP7170133B2 (ja) | 2018-11-06 | 2019-11-06 | ピリダジノン化合物およびその使用 |
| JP2022174578A Active JP7357135B2 (ja) | 2018-11-06 | 2022-10-31 | ピリダジノン化合物およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022174578A Active JP7357135B2 (ja) | 2018-11-06 | 2022-10-31 | ピリダジノン化合物およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US11236065B2 (https=) |
| EP (2) | EP4248972A3 (https=) |
| JP (2) | JP7170133B2 (https=) |
| KR (1) | KR102885525B1 (https=) |
| CN (1) | CN113272014B (https=) |
| AU (1) | AU2019376647B2 (https=) |
| BR (1) | BR112021008903A2 (https=) |
| CA (1) | CA3118908A1 (https=) |
| DK (1) | DK3877052T3 (https=) |
| EA (1) | EA202191082A1 (https=) |
| ES (1) | ES2957383T3 (https=) |
| IL (1) | IL282997B1 (https=) |
| MX (1) | MX2021005348A (https=) |
| PL (1) | PL3877052T3 (https=) |
| SG (1) | SG11202104710WA (https=) |
| WO (1) | WO2020097265A1 (https=) |
| ZA (1) | ZA202103231B (https=) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3728228A1 (en) | 2017-12-22 | 2020-10-28 | Ravenna Pharmaceuticals, Inc. | Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors |
| WO2019164852A1 (en) * | 2018-02-20 | 2019-08-29 | Edgewise Therapeutics, Inc. | Methods and compositions for treating movement disorders |
| DK3877376T3 (da) | 2018-11-06 | 2023-10-02 | Edgewise Therapeutics Inc | Pyridazinonforbindelser og anvendelser deraf |
| AU2019374812B2 (en) | 2018-11-06 | 2025-03-06 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| CA3118908A1 (en) | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| EP4149466A1 (en) * | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| WO2021231565A1 (en) * | 2020-05-13 | 2021-11-18 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
| EP4149621B1 (en) * | 2020-05-13 | 2024-10-30 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
| EP4149465A1 (en) * | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| KR20230035049A (ko) * | 2020-07-02 | 2023-03-10 | 데날리 테라퓨틱스 인크. | 화합물, 조성물 및 방법 |
| EP4433473A1 (en) * | 2021-11-17 | 2024-09-25 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| WO2024015527A1 (en) * | 2022-07-13 | 2024-01-18 | Bayesian Biotech, Llc | Therapeutic combinations of drugs, companion diagnostics and methods for dosaging and using them |
| CN120302976A (zh) | 2022-09-09 | 2025-07-11 | 艾知怀斯治疗学公司 | 用于治疗神经肌肉病状的哒嗪酮组合物 |
| CN121194963A (zh) | 2023-03-27 | 2025-12-23 | 艾知怀斯治疗学公司 | 喹啉酮酰胺类化合物及其用途 |
| WO2024206345A1 (en) | 2023-03-27 | 2024-10-03 | Edgewise Therapeutics, Inc. | Quinazoline dione compounds and uses thereof |
| WO2025207665A1 (en) * | 2024-03-26 | 2025-10-02 | Edgewise Therapeutics, Inc. | Quinolinone compounds and uses thereof |
| WO2025207622A1 (en) * | 2024-03-26 | 2025-10-02 | Edgewise Therapeutics, Inc. | Quinolinone, benzoxazinone, and quinoline compounds and uses thereof |
| WO2025207679A1 (en) * | 2024-03-26 | 2025-10-02 | Edgewise Therapeutics, Inc. | Quinazoline dione compounds and uses thereof |
| WO2025207677A1 (en) * | 2024-03-26 | 2025-10-02 | Edgewise Therapeutics, Inc. | Quinazolinone compounds and uses thereof |
| GB2640329A (en) * | 2024-04-09 | 2025-10-15 | Imperial College Innovations Ltd | Hedgehog acyltransferase inhibitors |
| WO2025215121A1 (en) * | 2024-04-09 | 2025-10-16 | Imperial College Innovations Limited | Hedgehog acyltransferase inhibitors |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE286354C (https=) | ||||
| JPS6140270A (ja) | 1984-08-01 | 1986-02-26 | Morishita Seiyaku Kk | ピリダジノン誘導体 |
| ES2131506T3 (es) | 1990-09-21 | 1999-08-01 | Rohm & Haas | Dihidropiridacinonas y piridacinonas como fungicidas. |
| US6334997B1 (en) | 1994-03-25 | 2002-01-01 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
| CN1087725C (zh) | 1994-03-25 | 2002-07-17 | 同位素技术有限公司 | 用氘代方法增强药物效果 |
| IL118631A (en) | 1995-06-27 | 2002-05-23 | Tanabe Seiyaku Co | History of pyridazinone and processes for their preparation |
| DE19629817A1 (de) | 1996-07-24 | 1998-01-29 | Hoechst Ag | Neue Imino-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten |
| NZ522882A (en) | 2000-06-05 | 2004-07-30 | Altana Pharma Bv | Pyridazinone compounds effective as beta-2-adrenoreceptor agonists as well as PDE4-inhibitors |
| US20040067955A1 (en) * | 2002-09-06 | 2004-04-08 | Fujisawa Pharmaceutical Co. Ltd. | Pyridazinone compound and pharmaceutical use thereof |
| CN1326852C (zh) | 2003-03-07 | 2007-07-18 | 兴和株式会社 | 苯并呋喃衍生物 |
| JP4890439B2 (ja) | 2005-03-07 | 2012-03-07 | 杏林製薬株式会社 | ピラゾロピリジン−４−イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤 |
| WO2007044796A2 (en) | 2005-10-11 | 2007-04-19 | Nps Pharmaceuticals, Inc. | Pyridazinone compounds as calcilytics |
| DE102005057924A1 (de) | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | Pyridazinonderivate |
| UA95644C2 (ru) | 2006-07-25 | 2011-08-25 | Сефалон, Инк. | Пиридазиноновые производные, фармацевтическая композиция и способ лечения заболеваний |
| AU2008219166B2 (en) | 2007-02-16 | 2013-05-16 | Amgen Inc. | Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors |
| DE102007025718A1 (de) | 2007-06-01 | 2008-12-04 | Merck Patent Gmbh | Pyridazinonderivate |
| DE102007025717A1 (de) | 2007-06-01 | 2008-12-11 | Merck Patent Gmbh | Arylether-pyridazinonderivate |
| DE102007032507A1 (de) | 2007-07-12 | 2009-04-02 | Merck Patent Gmbh | Pyridazinonderivate |
| GB0715087D0 (en) * | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
| DE102007038957A1 (de) | 2007-08-17 | 2009-02-19 | Merck Patent Gmbh | 6-Thioxo-pyridazinderivate |
| DE102008019907A1 (de) | 2008-04-21 | 2009-10-22 | Merck Patent Gmbh | Pyridazinonderivate |
| WO2009142732A2 (en) * | 2008-05-20 | 2009-11-26 | Cephalon, Inc. | Substituted pyridazinone derivatives as histamine-3 (h3) receptor ligands |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| AR081626A1 (es) * | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| WO2012021707A2 (en) | 2010-08-11 | 2012-02-16 | The Regents Of The University Of California | Premature-termination-codons readthrough compounds |
| BR112013007499A2 (pt) | 2010-09-01 | 2016-07-12 | Genentech Inc | piridazinonas - métodos de criação e usos |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| WO2013057101A1 (de) | 2011-10-17 | 2013-04-25 | Bayer Intellectual Property Gmbh | Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer |
| CN103570730A (zh) | 2012-08-01 | 2014-02-12 | 中国科学院上海药物研究所 | 具有桥环结构的稠环哒嗪酮类化合物及其制备方法和用途 |
| US20140073634A1 (en) | 2012-08-24 | 2014-03-13 | Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center | Heterocyclic modulators of hif activity for treatment of disease |
| US9566310B2 (en) | 2012-09-10 | 2017-02-14 | Board Of Regents Of The Nevada System Of Higher Education On Behalf Of The University Of Nevada, Reno | Methods of treating muscular dystrophy |
| US9216180B2 (en) | 2012-10-02 | 2015-12-22 | New York University | Pharmaceutical compositions and treatment of genetic diseases associated with nonsense mediated RNA decay |
| AU2013365926B9 (en) | 2012-12-21 | 2019-01-17 | Zenith Epigenetics Ltd. | Novel heterocyclic compounds as bromodomain inhibitors |
| EP2953944B1 (en) | 2013-02-07 | 2017-04-26 | Merck Patent GmbH | Pyridazinone-amides derivatives |
| MX365950B (es) | 2013-03-13 | 2019-06-19 | Flatley Discovery Lab Llc | Compuestos de piridazinona y metodos para el tratamiento de la fibrosis quistica. |
| WO2014189634A1 (en) * | 2013-04-19 | 2014-11-27 | University Of Iowa Research Foundation | Angiotensins in muscular dystrophy |
| US10555960B2 (en) * | 2015-06-05 | 2020-02-11 | Ptc Therapeutics, Inc. | Use of an aminoglycoside for nonsense mutation suppression and the treatment of disease |
| JP7007199B2 (ja) * | 2015-06-10 | 2022-02-10 | アソシアシオン・アンスティテュ・ドゥ・ミオロジー | デュシェンヌ型筋ジストロフィーのための併用療法 |
| CN106467495A (zh) | 2015-08-19 | 2017-03-01 | 中国科学院上海药物研究所 | 哒嗪酮类化合物、其制备方法、药物组合物及用途 |
| WO2017046117A1 (en) | 2015-09-15 | 2017-03-23 | Abbvie Inc. | Substituted isoxazolopyridazinones and isothiazolopyridazinones and methods of use |
| AU2017348186A1 (en) | 2016-10-26 | 2019-05-16 | Proteostasis Therapeutics, Inc | Pyridazine derivatives, compositions and methods for modulating CFTR |
| CA3041675A1 (en) | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc. | N-phenyl-2-(3-phenyl-6-oxo-1,6-dihydropyridazin-1-yl)acetamide derivatives for treating cystic fibrosis |
| WO2018081378A1 (en) * | 2016-10-26 | 2018-05-03 | Proteostasis Therapeutics, Inc. | Compounds, compositions, and methods for modulating cftr |
| EP3600322A1 (en) | 2017-03-28 | 2020-02-05 | Boehringer Ingelheim International GmbH | Nintedanib for use in methods for the treatment of muscular dystrophy |
| TWI902102B (zh) | 2017-04-06 | 2025-10-21 | 美商富曼西公司 | 殺真菌之噁二唑 |
| US20180303821A1 (en) | 2017-04-24 | 2018-10-25 | BraneQuest, Inc. | Membrane active molecules |
| BE1025518B1 (fr) | 2017-08-30 | 2019-04-03 | E2 Drives Sa | Groupe motopropulseur |
| JP2020533316A (ja) * | 2017-09-06 | 2020-11-19 | トランスレイショナル・ドラッグ・ディベロップメント・エルエルシー | アミノベンゾイミダゾール誘導体、治療、およびヒストン脱アセチル化酵素を阻害する方法 |
| EP3700516B1 (en) | 2017-10-27 | 2024-01-24 | Sonic Master Limited | Inhibitors of dux4 induction for regulation of muscle function |
| CN112166181B (zh) | 2018-05-17 | 2024-03-08 | 保尔特纺织品公司 | 用于改善重组蛋白分泌的sec经修饰菌株 |
| EP4685140A1 (en) | 2018-06-04 | 2026-01-28 | Ohio State Innovation Foundation | Eaat2 activators and methods of using thereof |
| EP3828174A4 (en) | 2018-07-19 | 2022-08-17 | Sumitomo Pharma Co., Ltd. | PYRIDAZINONE DERIVATIVE |
| CN108947912B (zh) | 2018-07-31 | 2021-10-01 | 中国人民解放军总医院 | 一种靶向Neddylation通路的抗肿瘤化合物 |
| CA3118908A1 (en) * | 2018-11-06 | 2020-05-14 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| AU2019374812B2 (en) | 2018-11-06 | 2025-03-06 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| DK3877376T3 (da) | 2018-11-06 | 2023-10-02 | Edgewise Therapeutics Inc | Pyridazinonforbindelser og anvendelser deraf |
| EP4149621B1 (en) | 2020-05-13 | 2024-10-30 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
| WO2021231565A1 (en) | 2020-05-13 | 2021-11-18 | Edgewise Therapeutics, Inc. | Pyridazinone compounds for the treatment of neuromuscular diseases |
| EP4149467A1 (en) | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| EP4149466A1 (en) | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| EP4149465A1 (en) | 2020-05-13 | 2023-03-22 | Edgewise Therapeutics, Inc. | Substituted pyridazinone for use in the treatment of neuromuscular diseases |
| JP7694135B2 (ja) | 2021-05-11 | 2025-06-18 | 株式会社大林組 | 接続構造及び接続方法 |
| EP4433473A1 (en) | 2021-11-17 | 2024-09-25 | Edgewise Therapeutics, Inc. | Pyridazinone compounds and uses thereof |
| CN119317621A (zh) | 2022-05-11 | 2025-01-14 | 艾知怀斯治疗学公司 | 制备哒嗪酮化合物的方法 |
| CN120302976A (zh) | 2022-09-09 | 2025-07-11 | 艾知怀斯治疗学公司 | 用于治疗神经肌肉病状的哒嗪酮组合物 |
-
2019
- 2019-11-06 CA CA3118908A patent/CA3118908A1/en active Pending
- 2019-11-06 WO PCT/US2019/060155 patent/WO2020097265A1/en not_active Ceased
- 2019-11-06 JP JP2021524225A patent/JP7170133B2/ja active Active
- 2019-11-06 SG SG11202104710WA patent/SG11202104710WA/en unknown
- 2019-11-06 BR BR112021008903A patent/BR112021008903A2/pt unknown
- 2019-11-06 AU AU2019376647A patent/AU2019376647B2/en active Active
- 2019-11-06 EA EA202191082A patent/EA202191082A1/ru unknown
- 2019-11-06 ES ES19835996T patent/ES2957383T3/es active Active
- 2019-11-06 DK DK19835996.0T patent/DK3877052T3/da active
- 2019-11-06 EP EP23188998.1A patent/EP4248972A3/en active Pending
- 2019-11-06 CN CN201980088117.0A patent/CN113272014B/zh active Active
- 2019-11-06 PL PL19835996.0T patent/PL3877052T3/pl unknown
- 2019-11-06 EP EP19835996.0A patent/EP3877052B1/en active Active
- 2019-11-06 KR KR1020217016677A patent/KR102885525B1/ko active Active
- 2019-11-06 MX MX2021005348A patent/MX2021005348A/es unknown
-
2020
- 2020-11-03 US US17/088,466 patent/US11236065B2/en active Active
-
2021
- 2021-05-06 IL IL282997A patent/IL282997B1/en unknown
- 2021-05-12 ZA ZA2021/03231A patent/ZA202103231B/en unknown
- 2021-11-23 US US17/534,355 patent/US12415794B2/en active Active
-
2022
- 2022-10-31 JP JP2022174578A patent/JP7357135B2/ja active Active
-
2025
- 2025-07-10 US US19/266,018 patent/US20250340526A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2020097265A5 (https=) | ||
| JP2022506685A5 (https=) | ||
| JP7357135B2 (ja) | ピリダジノン化合物およびその使用 | |
| RU2472509C2 (ru) | Способ лечения артрита | |
| JP2020510010A5 (https=) | ||
| BR112021007861A2 (pt) | compostos heterocíclicos substituídos por amida | |
| JP2005535698A5 (https=) | ||
| JP2005509642A5 (https=) | ||
| JPWO2021244831A5 (https=) | ||
| RU2215000C2 (ru) | Производные солей пиридиния, способ их получения, фармацевтические композиции на их основе и способы лечения | |
| JP2024518792A (ja) | 置換ヘテロ環化合物 | |
| BR112013000050B1 (pt) | Compostos de carbamato de fenila e composição farmacêutica | |
| JPWO2020097258A5 (https=) | ||
| Artusio et al. | STUDIES ON THE INTER-RELATIONSHIP OF CERTAIN CHOLINERGIC COMPOUNDS: IV. Anti-Curare Action in Anesthetized Man | |
| JP2010533720A (ja) | 不安を処置するための方法 | |
| JP2025528115A (ja) | 腫瘍治療のための、放射線治療と組み合わせたピペラジン化合物の使用 | |
| JPWO2019232130A5 (https=) | ||
| JP2019517500A5 (https=) | ||
| JP2004501079A5 (https=) | ||
| RU2002102076A (ru) | Фармацевтическая композиция, содержащая сибутрамин и орлистат | |
| WO2019108873A1 (en) | Methods and compositions for treating multiple sclerosis | |
| JPWO2003084537A1 (ja) | 胃食物受容能障害治療薬 | |
| Kewenter et al. | The effect of some spasmolytic drugs on the choledocho-duodenal junction in man | |
| JPWO2020023324A5 (https=) | ||
| JP4598674B2 (ja) | 統合失調症治療剤 |